Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells

Cancer Research

Volumn 56, Issue 7, 1996, Pages 1556-1563

  Rea, Daniel ^a   Parker, Malcolm G ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; EXON; GENE EXPRESSION; GENE INDUCTION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; RNA SPLICING; TARGET CELL;

ANIMALS; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; EXONS; FEMALE; HUMANS; MOLECULAR WEIGHT; RABBITS; RECEPTORS, ESTROGEN; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0029923438     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Jordan, V. C. Biochemical pharmacology of antiestrogen action. Pharmacol. Rev., 36. 245-76, 1984.
2. Bentley, A., Fentiman, I. S., Rubens, R. D., Cuzick, J., Crossley, E., Durrant, K., Harris, A., Clarke, M , Collins, R , Godwin, J , Gray, R., Greaves, E , Harwood, C., Mead, G., Peto, R. and Wheatley, K. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women Part 2 Lancet, 339: 71-85, 1992.
3. McGuire, W. L., and Clark, G , M The prognostic role of progesterone receptors in human breast cancer. Semin. Oncol., 10: 2-6, 1983.
4. Wiebe, V. J., Osborne, C. K., Fuqua, S. A. W., and DeGregorio, M. W. Tamoxifen resistance in breast cancer Crit. Rev. Oncol. Hematol., 14: 173-188, 1993.
5. Clarke, R , and Lippman, M E. Acquisition of antiestrogen resistance in breast cancer. In B A. Teicher (ed.), Drug Resistance in Oncology, pp. 501-531. New York: Marcel Dekker, Inc., 1992.
6. Osbourne, C. Tamoxifen metabolism as a mechanism for resistance Endocr. Relat Cancer, 2: 53-58, 1995
7. Rea, D. W., and Parker, M. G. Structure and function of the estrogen-receptor in relation to its altered sensitivity to estradiol and tamoxifen. Endocr. Relat. Cancer, 2: 13-17, 1995.
8. Tora, L., White, J., Brou, C., Tasset, D , Webster, N., Scheer, E , and Chambon, P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell, 59: 477-487, 1989.
9. Fuqua, S. A., Fitzgerald, S. D., Chamness, G. C., Tandon, A K , McDonnell, D P., Nawaz, Z., O'Malley, B. W., and McGuire, W. L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity Cancer Res , 51: 105-109, 1991.
10. Fuqua, S. A. W , Fitzgerald, S. D., Allred, D. C., Elledge, R. M., Nawaz, Z., McDonnell, D. P., O'Malley, B. W., Greene, G L., and McGuire, W. L. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res., 52. 483-486, 1992.
11. Wang, Y., and Miksicek, R. J. Identification of a dominant negative form of the human estrogen receptor. Mol. Endocrinol., 5 1707-1715, 1991.
12. Miksicek, R. J , Lei, Y., and Wang, Y. Exon skipping gives rise to alternately spliced forms of the estrogen receptor in breast tumour cells. Breast Cancer Res. Treat., 26: 163-174, 1993.
13. Koehorst, S. G. A , Jacobs, H M., Thijssen, J. H. H., and Blankenstein, M. A Wild type and alternatively spliced estrogen receptor messenger RNA in human meningioma tissue and MCF7 breast cancer cells. J. Steroid Biochem. Mol. Biol., 45: 227-233, 1993.
14. Pfeffer, U , Fecarotta, E , and Vidali, G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res., 55. 2158-2165, 1995.
15. Pfeffer, U , Fecarotta, E , Castagnetta, L., and Vidali, G Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer Res , 53: 731-743, 1993.
16. Gotteland, M , Desauty, G., Delarue, J , Liu, L., and May, E. Human estrogen receptor messenger RNA variants in both normal and tumour breast tissues Mol Cell. Endocrinol., 112: 1-13, 1995.
17. Berry, M , Metzger, D , and Chambon, P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J., 9 2811-2818, 1990.
18. Zhang, Q. X., Borg, A., and Fuqua, S. A. W. An exon-5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer Cancer Res., 53: 5882-5884, 1993.
19. Daffada, A. A. I., Johnston, S R. D., Smith, I. E., Detre, S , King, N., and Dowsett, M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res., 55: 288-293, 1995.
20. Danielian, P. S., White, R., Lees, J. A., and Parker, M G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors EMBO J., 11: 1025-1033, 1992.
21. Chen, C., and Okayama, H. High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol., 7: 2745-2752, 1987.
22. Danielian, P. S., White, R., Hoare, S. A , Fawell, S. E., and Parker, M. G. Identification of residues in the estrogen receptor which confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol., 7: 232-240, 1993.
23. De Wet, J. R., Wood K. V., Deluca, M., Helinski, D. R., and Subramani, S. Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol., 7: 725-737, 1987
24. Sleigh, M. J. A nonchromatographic assay for expression of the chloramphenicol acetyltransferase gene in eucaryotic cells. Anal. Biochem., 156: 251-256, 1986.
25. Dauvois, S., Danielian, P. S., White, R., and Parker, M G Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl. Acad. Sci USA, 89: 4037-4041, 1992
26. Fawell, S. E., White, R., Hoare, S., Sydenham, M , Page, M , and Parker, M. G. Inhibition of estrogen receptor-DNA binding by the 'pure' antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimenzation. Proc. Natl. Acad. Sci. USA, 87: 6883-6887, 1990.
27. Lahooti, H., White, R , Danielian, P. S., and Parker, M. G. Characterization of ligand-dependent phosphorylation of the estrogen receptor Mol. Endocrinol , 8: 182-188, 1994.
28. Ham, J., Thomson, A , Needham, M , Webb, P , and Parker, M. G. Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus Nucleic Acids Res , 16: 5263-5276, 1988
29. Church, G. M., and Gilbert, W. Genomic sequencing. Proc. Natl. Acad. Sci. USA, 81: 1991-1995, 1984.
30. Garcia-Morales, P , Saceda, M , Kenney, N , Kim, N., Salomon, D. S., Gottardis, M. M., Solomon, H. B., Sholler, P. F., Jordan, V. C., and Martin, M. B. Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. J. Biol Chem., 269: 16896-16901, 1994
31. Martinez, E., and Wahli, W Cooperative binding of estrogen receptor to imperfect estrogen-responsive DNA elements correlates with their synergistic hormone-dependent enhancer activity EMBO J., 8: 3781-3791, 1989.
32. Catherino, W H., and Jordan, V. C. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue Cancer Lett , 92. 39-4, 1995.
33. Brown, A. M., Jeltsch, J-M., Roberts, M , and Chambon, P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc. Natl. Acad. Sci USA, 81: 6344-6348, 1984.
34. Kastner, P., Krust, A , Turcotte, B., Stropp, U., Tora, L , Gronemeyer, H , and Chambon, P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B EMBO J., 9. 1603-1614, 1990.
35. Iveson, T. J., Smith, I. E , Ahem, J., Smithers, D. A., Tunet, P. F., and Dowsett, M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res., 53: 266-270, 1993.
36. Johnston, S R. D , Smith, I. E., Doody, D., Jacobs, S , Robenshaw, H., and Dowsett, M The clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res., 54. 5875-5881, 1994.
37. Howell, A , DeFriend, D , Robetson, J , Blarney, R., and Walton, p Response to a specific antioestroaen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345: 29-30, 1995.
38. Miksicek, R. J. Steroid receptor variants and their potential role in cancer. In. M. Parker (ed.), Seminars in Cancer Biology. Steroids and Their Receptors, pp 369-379. London: Academic Press, 1994.
39. McGuire, W , Chamness, G C , and Fuqua, SAW Estrogen receptor variants in clinical breast cancer Mol Endocrinol , 5: 1571-1577, 1991.
40. Metzger, D , White, J. H., and Chambon, P. The human oestrogen receptor functions in yeast. Nature (Lond.), 334: 31-36, 1988.
41. Fuqua, S. A. W. Estrogen receptor mutagenesis and hormone resistance. Cancer (Phila.), 74: 1026-1029, 1994.
42. Neri, C , Colomb, E , Roux-Dosseto, M., and Martin, P-M Distinct effects of gonadotropin-releasing hormone analogs and 4-hydroxytamoxifen on pS2 mRNA expression with respect to cell proliferation in MCF-7 breast cancer cells Anticancer Res , 11: 411-416, 1991.
43. 1. Cancer Res , 54: 1587-1595, 1994.
44. Fuqua, S A. W., and Wolf, D M. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat., 35: 233-241, 1995.
45. Fuqua, S. A. W , Wiltschke, C., Castles, C., Wolf, D., and Allred, D C A role for estrogen-receptor variants in endocrine resistance. Endocr. Related Cancer, 2: 19-25, 1995.
46. Brunner, N., Frandsen, T. L., Holst-Hansen, C., Bei, M., Thompson, E. W , Wakeling, A E , Lippman, M. E , and Clarke, R MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res., 53: 3229-3223, 1993.
47. DeFriend, D., Anderson, E., Bell, J., Wilks, D , West, C., Mansel, R , and Howell, A Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br. J. Cancer, 70: 204-211, 1994.
48. Fujimoto, N., and Katzenellenbogen, B. S. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signalling pathways in breast cancer cells: antiestrogen-selectivity and promoter-dependence. Mol. Endocrinol., 8: 296-304, 1994.
49. Miller, W. R., Watson, D. M. Jack, W , Chetty, U., and Elton, R. A. Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat., 26: 89-94, 1993.
50. Mahfoudi, A , Roulet, E , Dauvois, S , Parker, M. G., and Wahh, W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc. Natl. Acad Sci. USA, 92: 4206-4210, 1995.
51. Jordan, V. C., Catherino, W. L., and Wolf, D. M. Drug-resistance to tamoxifen: mutant estrogen receptors as a potential mechanism of tamoxifen-stimulated tumor growth. Endocr. Relat Cancer, 2: 45-51, 1995
52. Jian, S-Y , Langan-Fahey, S. M , Stella, A. L., McCague, R , and Jordan, V. C. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol. Endocrinol., 6: 2167-2174, 1992.
53. Wolf, D. M , and Jordan, V C. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat., 31: 129-138, 1994.
54. Karnik, P. S., Kulkarni, S., Liu, X. P., Budd, G. T., and Bukowski, R. M Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res., 54: 349-353, 1994
55. Roodi, N., Bailey, L. R., Kao, W-Y., Verrier, C. S., Yee, C. J., Dupont, W. D , and Parl, F. F. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst., 87: 446-450, 1995.
56. Ignar-Trowbridge, D. M., Teng, C. T., Ross, K. A , Parker, M. G., Korach, K. S., and McLachlan, J. A. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol , 7 992-998, 1993.